Biogen Idec (BIIB) missed analyst expectations last quarter, but will try to make up for it when it announces its latest results on Tuesday.

Expectations

Analysts currently expect Biogen Idec to come in with earnings of $1.56 per share on revenues of $1.33 billion. Estimates range from $1.49 per share to $1.60 per share. Over the past three months, the average estimate has moved up from $1.54.

Stock Movement

The biggest recent change for the stock came on June 14, 2012, when it rose $4.44 per share to $138.66. Looking at change over the last three months, from April 23, 2012 and July 18, 2012, the stock price is up $19.11 (15.2%), from $125.85 to $144.96.

Company Fundamental Trends

The impending earnings announcement offers the opportunity expand on positive earnings momentum gained over last three quarters. Net income rose 38.5% in the third quarter of the last fiscal year and 25% in the fourth quarter of the last fiscal year before increasing again in the first quarter. On the top line, the company is looking to build on three-straight revenue increases heading into this earnings announcement. Revenue increased 11.4% in the third quarter of the last fiscal year and 8.8% in the fourth quarter of the last fiscal year before climbing again in the first quarter. Stock Ratings

Analysts are bullish on the stock as 12 analysts rate it as a buy and there are no sell ratings. Analyst sentiment has been improving recently, as the average rating risen slightly over the past three months.

Last Quarter's Results

In the first quarter, profit rose 2.8% to $302.7 million ($1.25 a share) from $294.3 million ($1.20 a share) the year earlier, but fell short analyst expectations. Revenue rose 7.4% to $1.29 billion from $1.2 billion.

Summary

Reporting Period: 2Q

Date of Release: Tuesday, July 24, 2012 before market open

EPS: $1.56

Revenue Estimate: $1.33 billion

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)